市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Omeros Corporation | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | -3.0 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.50 |
|
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.40% |
| 机构持股比例 | 47.30% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ingalls & Snyder Llc | 31 Dec 2025 | 3,448,699 |
| Stifel Financial Corp | 31 Dec 2025 | 1,809,766 |
| Nomura Holdings Inc | 31 Dec 2025 | 655,021 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (HC Wainwright & Co., 233.89%) | 购买 |
| 中 | 38.00 (217.20%) | |
| 低 | 36.00 (D. Boral Capital, 200.50%) | 购买 |
| 平均值 | 38.00 (217.20%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 13.06 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 27 Jan 2026 | 36.00 (200.50%) | 购买 | 12.67 |
| 08 Jan 2026 | 36.00 (200.50%) | 购买 | 13.45 | |
| HC Wainwright & Co. | 08 Jan 2026 | 40.00 (233.89%) | 购买 | 13.45 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| DEMOPULOS GREGORY A MD | - | 11.75 | -357,678 | -4,202,717 |
| 累积净数量 | -357,678 | |||
| 累积净值 ($) | -4,202,717 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 11.75 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| DEMOPULOS GREGORY A MD | 职员 | 18 Feb 2026 | 处理 (-) | 357,678 | 11.75 | 4,202,717 |
| DEMOPULOS GREGORY A MD | 职员 | 18 Feb 2026 | 执行期权 | 400,000 | - | - |
| 日期 | 类型 | 细节 |
|---|---|---|
| 27 Jan 2026 | 公告 | Omeros Announces First Commercial Sales of YARTEMLEA® |
| 26 Dec 2025 | 公告 | Omeros Announces New Date for YARTEMLEA® Approval Conference Call |
| 24 Dec 2025 | 公告 | FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合